A Study of Lanabecestat in Participants With Severe Kidney Impairment Compared to Healthy Participants

• Status: Withdrawn
• Trial end date: 2019-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to determine whether lanabecestat can be safely prescribed in participants with kidney impairment without a dose adjustment.

Participants will be on study for up to 6 weeks; this includes a 2-week screening and a follow-up about 10 days after final drug administration.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Eli Lilly and Company
• Collaborator: AstraZeneca

Criteria

Inclusion Criteria:

• Have a body mass index (BMI) of 19 to 40 kilograms per meter square (kg/m²)

Exclusion Criteria:

• Have a history of or current significant ophthalmic disease, particularly any eye problem involving the retina

• Have moderate or severe vitiligo or any other clinically significant disorder of skin or hair pigmentation

• Have acute unstable neuropsychiatric disease

• Have active or uncontrolled neurologic disease, or clinically significant head injury